Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Royalty Pharma will pay Teva $500 million to finance the joint costs of development, of which $75 million is R&D co-funding ...

Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo. Jeffrey D. Dunn, PharmD, MBA: What therapies are being used? Are they generally covered by different books of ...

WORCESTER (CBS) - Vitiligo is a common condition that causes people to lose pigment in their skin. Michael Jackson famously suffered from it, allegedly bleaching his skin to make it look more even.

The application is supported by data from the phase 3 TRuE-V clinical trial program. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application for ...

Sarah Hayden owns a lot of turtlenecks. She also has chunky necklaces and tons of makeup – anything to cover up the blotchy white skin on her face, neck, hands and knees. When she was about 23, Hayden ...

Experts provide closing pearls regarding the current and prospective treatment landscape of vitiligo. Jeffrey D. Dunn, PharmD, MBA: This has been an awesome discussion. Before we conclude, I’d like to ...

ATLANTA - At 57, Perry Whaley has been living with vitiligo, an autoimmune disorder that has caused him to lose pigment in his skin, for more than half his life. Whaley said, if he had been offered a ...

Vitiligo is an autoimmune condition that causes areas of skin to lose color or pigment. It isn’t just visible to others. You can see it on yourself. And I talk with people all the time about how this ...

Oral JAK inhibitors carry potentially serious adverse reactions, including pancytopenia, malignancy, and infections. In contrast, these risks are not associated with topical JAK inhibitors, prompting ...